Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SHR2554 + TLN-121 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SHR2554 | SHR-2554|SHR 2554|TLN254|TLN-254|TLN 254|Zeprumetostat | EZH2 inhibitor 20 | SHR2554 inhibits wild-type and mutant EZH2, which potentially decreases intracellular H3K27me3 and reduces tumor growth (PMID: 38190117). | |
| TLN-121 | TLN121|TLN 121 | Limited information is currently available on TLN-121 (Jul 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07082803 | Phase I | TLN-121 SHR2554 + TLN-121 | TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas | Recruiting | USA | CAN | AUS | 0 |